Netherlands-based investment group Gilde Healthcare has finally closed its new Venture & Growth VI fund with committed funding of €740 million, well ahead of its origi
Netherlands-based investment group Gilde Healthcare has raised €600 million ($658 million) for a new transatlantic fund intended to support innovative ventures in digital
It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt.